Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
about
Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavitiesPrognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.The role of G protein-coupled receptors in lymphoid malignancies.Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
P2860
Q33758646-81B476F6-F3AD-4F46-BCBC-197A092A677EQ36414139-F9576F4A-5304-4452-8B98-17C1AB791815Q36681461-A90C4F59-28A8-439D-953A-64E84AB3A857Q36771814-3F139625-6F9D-4CE3-B7C8-65A0F34C4D9EQ38915272-721A3C1C-31BE-4B3D-9A84-338F58AF2129Q39470633-2DC8D848-44AD-468C-9C14-DC05ED32FF2DQ40126382-327D482B-D11B-4E3C-A773-C6BA001A6151Q40796551-1E27178E-358F-46A9-B02F-EDE2C08AD29CQ41507351-FD349C92-4BB2-4A40-BDC8-031DCBBA2D1EQ42006192-557B4F71-2672-4106-B0FB-E87C7CFDD391Q47737291-E566893F-1699-4838-816E-810160208B31Q47960121-13C02CFD-4918-40F5-9A36-1DBA40928AA1Q48108703-0C0603E5-022C-472D-A4C8-E33F9968E5F8Q55282193-3DDE2E9C-0583-4C2B-9FA3-4CE6B26A81EB
P2860
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@ast
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@en
type
label
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@ast
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@en
prefLabel
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@ast
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@en
P2093
P2860
P50
P356
P1433
P1476
Dysregulated CXCR4 expression ...... diffuse large B-cell lymphoma
@en
P2093
Andrés J M Ferreri
April Chiu
Azahara Martinez-Lopez
Carlo Visco
Eric D Hsi
Ganiraju C Manyam
Jane N Winter
Jiayu Chen
John P Farnen
Jooryung Huh
P2860
P304
P356
10.18632/ONCOTARGET.3343
P407
P50
P577
2015-03-01T00:00:00Z